NCT03627936View on ClinicalTrials.gov

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 7, 2018

Primary Completion Date

September 2, 2018

Study Completion Date

September 2, 2018

Conditions
Healthy Participants
Interventions
DRUG

Lorcaserin manufactured at Zofingen

Lorcaserin XR tablets manufactured at Zofingen.

DRUG

Lorcaserin manufactured at Kawashima

Lorcaserin XR tablets manufactured at Kawashima.

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT03627936 - A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants | Biotech Hunter | Biotech Hunter